Binnopharm Group, one of Russia’s leading pharmaceutical companies, and the Research Institute of Clinical and Experimental Lymphology (NIIKEL), a branch of the Instutute of Cytology and Genetics of the Siberian Branch of the RAS, will begin working together in the coming months on a new drug for the treatment of gastrointestinal diseases. The development is expected to be ready for commercial production by the end of 2027, followed by the registration process and entry into the Russian market. Binnopharm Group estimated the market potential of the drug to be at least 10 billion rubles, according to Kommersant.
NIIKEL researchers, who have many years of scientific experience in the field of pharmacological technologies, will be in charge of the research and drug synthesis, as well as the study of the drug’s properties. After that, the technology will be transferred to the Binnopharm Group production site, where GI drugs production is one of the key areas of activity. Experts interviewed by the publication believe that such a collaboration creates a platform for bringing domestic innovations to the global level.
«Our institute has extensive experience in pharmacological technologies, as we have been conducting research in this area for more than 30 years. Today, there is no doubt that Russia must develop and manufacture its original drugs», — Maxim Korolev, head of NIIKEL, told the publication.
New clinical guidelines of the Ministry of Health of the Russian Federation for the treatment of acute intestinal infections in adults have been in effect in Russia since 2025, based on the document published by the Ministry in January. The Ministry hopes that their recommendations will allow health workers to improve patient treatment. The transition to clinical guidelines began in the country in 2022. It was planned as a phased process and ended on January 1 of this year. Now all the guidelines (250 documents for various diseases) will become mandatory.
The desire of the public health system to systematize approaches in this area reflects the need to find new and effective approaches to the treatment of these diseases. The incidence of intestinal infections of known and unknown etiology is about 400 cases per 100 000 people each year. The annual economic damage caused by such diseases to the Russian economy is estimated at about 40 billion rubles, but can actually be much higher.
Earlier, Binnopharm Group published its financial results for 2024 in compliance with IFRS. The company’s net revenue increased by 12,9% (+4.2 billion rubles) last year, amounting to 36,7 billion rubles, compared to 32,5 billion rubles a year earlier. The company’s production sites have produced 363 million packages of medicines. According to Kommersant, Binnopharm Group has more than 20 prescription and over-the-counter gastroenterology drugs in its portfolio.
